Evaluation of the meropenem dosage and administration schedule in patients with bacteremia initial therapy

The standard meropenem (MEPM) regimen allowed by insurance in Japan is 0.5 g two or three times a day. Differences in dosages and administration schedules in Japan were evaluated. Patients with bacteremia for whom MEPM was used as the initial treatment at our institution between 2016 and 2021 were i...

Full description

Saved in:
Bibliographic Details
Published in:Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy 2023-08, Vol.29 (8), p.749-753
Main Authors: Tai, Tatsuya, Yamamoto, Takaaki, Yamaguchi, Kazunori, Watanabe, Masahiro, Tanaka, Hiroaki, Muraki, Yuichi, Kosaka, Shinji
Format: Article
Language:English
Subjects:
Antimicrobial stewardship
Carbapenem
Mortality rate
PK/PD
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The standard meropenem (MEPM) regimen allowed by insurance in Japan is 0.5 g two or three times a day. Differences in dosages and administration schedules in Japan were evaluated. Patients with bacteremia for whom MEPM was used as the initial treatment at our institution between 2016 and 2021 were included. We retrospectively investigated patients classified into two groups: those treated according to severe infections (high-dose groupand others (low-dose group). After propensity score matching, we compared the probability of achieving free drug blood levels above the minimum inhibitory concentration (MIC) in 24 h (%fT > MIC) and outcomes. The probability of 100% fT > MIC was significantly higher in the high-dose group (96.4% vs 74.5%, odds ratio [OR] = 0.3, 95% confidence interval [CI] = 0.2–0.4, P = 
ISSN:1341-321X
1437-7780
DOI:10.1016/j.jiac.2023.04.004